An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year. Clinical trials have shown TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sanjay S., Winkle, Peter, Faccin, Alice, Nordio, Francesco, LeFevre, Inge, Tsoukas, Claudia Galindo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Novel Vaccines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583633/
https://www.ncbi.nlm.nih.gov/pubmed/37846724
http://dx.doi.org/10.1080/21645515.2023.2254964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583633/
https://www.ncbi.nlm.nih.gov/pubmed/37846724
http://dx.doi.org/10.1080/21645515.2023.2254964

Ejemplares similares